公开(公告)号：US20190330376A1

公开(公告)日：2019-10-31

申请号：US16475121

申请日：2017-12-29

Applicant: Development Center for Biotechnology

Inventor： Chen-Li Chien ,  Gregory Jiann Chen ,  Chuan-Lung Hsu ,  Jei-Hwa Yu ,  Hsien-Yu Tsai ,  Show-Shan Sheu ,  Wei-Jung Chang ,  Chia-Cheng Wu

IPC: C07K16/46 ,  C07K14/745

Abstract: A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.